Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its pipeline products include ELS001/ELS007, a pharmaceutical grade L-glutamine, which has completed phase 3 clinical trial to treat sickle cell disease; ELS004, a pharmaceutical grade L-glutamine which has completed phase 1 clinical study to treat diverticulosis; ELS005 in preclinical study for the use and combination of KM10544 to treat blood cancers; ELS003, a lab device/research tool in preclinical study to measure transmittance of cell sheet; and ELS002, a chondrocyte cell sheet technology to replace knee cartilage replacement or to treat osteoarthritis is in preclinical study. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor (KM10544) for the treatment of cancers. The company was founded in 2000 and is headquartered in Torrance, California.